In May 2016, the FDA issued an official warning about impulse-control problems related to use of the drug Abilify.
“Patients and caregivers should be alert for uncontrollable and excessive urges and behaviors while taking aripiprazole.”
“Although pathological gambling is listed as a reported side effect in the current aripiprazole drug labels, this description does not entirely reflect the nature of the impulse-control risk FDA identified.”
These after-effects of Abilify were enough to warrant multiple lawsuits being filed against Bristol-Myers Squibb and Otsuka America Pharmaceuticals for failing to list all possible side effects of the drug.
Abilify Lawsuits have been filed against the Abilify manufacturers by both patients and their families seeking compensation for injuries, including the severe emotional damage caused by this drug and these side effects.
In December 2014, the JAMA International Medical Journal published an original investigation report titled “Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs.”
Research has suggested that Abilify side-effects may impact an individual’s impulse control, leading to gambling addictions or other compulsive behavior that can have a horrifying impact on an individual’s financial situation, family, employment, emotional conditions, and overall quality of life.
A gambling addiction caused by Abilify can have a devastating impact, leading to:
The first Abilify related settlement was for $515M and was finalized in 2007 between Bristol-Myers Squibb and the U.S. Justice Department.
Multiple Abilify Lawsuits are currently being filed against Bristol-Myers Squibb for failing to disclose the compulsive behaviors as a possible side effect of Abilify, and settlement amounts for Abilify lawsuits are likely to be substantial.
Aripiprazole, also known by its brand name “Abilify“ is an atypical antipsychotic drug. Abilify can treat psychotic conditions like depression, schizophrenia, bipolar disorder, Tourette syndrome and others. It can also be prescribed to treat irritability associated with autism.
Aripiprazole was developed by Otsuka Pharmaceutical Co., Ltd. in Japan. In the United States, Otsuka America markets Abilify jointly with Bristol-Myers Squibb. According to IMS Health, sales of Abilify were more than $9 billion during 2014.
Doctors issue 8.7 million prescriptions of Abilify a year, and this number is growing.
The U.S. Food and Drug Administration (FDA) initially approved Abilify in 2002 as a treatment for schizophrenia.
Schizophrenia is relatively rare condition, and numbers of prescriptions for Abilify were not significant for manufacturers. Otsuka and Bristol-Myers applied for FDA approval to use Abilify for more conditions. Once the FDA approved other uses of Abilify, the drug became a profitable resource for manufacturers.
In combination with other drugs, Abilify is marketed today as an atypical antipsychotic drug for treating major depressions, bipolar disorder, and irritability associated with autism.
Manufacturers of Abilify market the drug as an additional treatment, which in combination with other anti-depressants can help to treat mental illnesses. However, this very popular drug is also linked to serious side effects like compulsive gambling and shopping, sexual dysfunction and even suicidal thoughts.
Elderly people with psychosis related to dementia (for example, an inability to perform daily activities as a result of increased memory loss), treated with antipsychotic medicines including Abilify, are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of people with dementia-related psychosis. Antidepressants may increase suicidal thoughts or behaviors in some children, teenagers, and young adults, especially within the first few months of treatment or when the dose is changed. ABILIFY is not approved for use in pediatric patients with depression
Abilify as an antipsychotic drug with a list of devastating side effects, that manufacturers failed to properly warn the public of in a timely manner:
Have you seen a commercial about Abilify Lawsuits? You may have seen our “Compulsive Gambling Side-effect” commercial on your favorite nationally televised shows.
“Compulsive gambling can have a devastating impact on patients’ lives, even leading to severe financial harm. If you have become a compulsive gambler while taking Abilify, you may be entitled to a significant cash award.”
Patients who were prescribed Abilify for both approved and unapproved uses and who suffered severe consequences as a result may qualify to file an Abilify dangerous drug lawsuit.
If you or your loved one has suffered from compulsive behaviors due to Abilify use, please contact us immediately to have an attorney determine if you have a valid Abilify case.
Symptoms of Abilify compulsive gambling – its most commonly cited side effect – include:
There are strict deadlines that must be met for Abilify lawsuit settlements. Missed deadlines can result in ineligibility to receive a future settlement. To secure the best chance of being awarded a settlement, you should begin the process immediately. Please call or fill out the form right now to have a free evaluation of your Abilify case.
Once you have spoken to an Abilify lawsuit attorney, they will evaluate your case based on your unique facts.
If your answers meet the requirements for an Abilify Lawsuit, you may become eligible to receive a settlement to compensate you for Abilify damages, once your lawsuit has been filed.
Abilify® is a registered trademark of Bristol-Myers Squibb and Otsuka America Pharmaceutical